Stay updated on SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial
Sign up to get notified when there's something new on the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page.

Latest updates to the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check34 days agoNo Change Detected
- Check41 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check48 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check56 days agoChange DetectedThe latest update on January 24, 2025, includes new results on the efficacy of Pembrolizumab in NSCLC maintenance therapy, along with detailed response rates using RECIST criteria and immune-related progression-free survival metrics, while previous submissions from November 2024 have been removed.SummaryDifference13%
- Check63 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check70 days agoChange DetectedThe type of intervention has been updated from version v2.13.3 to v2.14.0.SummaryDifference0.2%
Stay in the know with updates to SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SWIPE: Pembrolizumab Switch in NSCLC Clinical Trial page.